These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 16296874)

  • 1. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters.
    Kasiakou SK; Lawrence KR; Choulis N; Falagas ME
    Drugs; 2005; 65(17):2499-511. PubMed ID: 16296874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
    Waineo MF; Kuhn TC; Brown DL
    J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.
    Dhaese S; Heffernan A; Liu D; Abdul-Aziz MH; Stove V; Tam VH; Lipman J; Roberts JA; De Waele JJ
    Clin Pharmacokinet; 2020 Oct; 59(10):1237-1250. PubMed ID: 32710435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review.
    Burgess SV; Mabasa VH; Chow I; Ensom MH
    Ann Pharmacother; 2015 Mar; 49(3):311-22. PubMed ID: 25575975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
    Georges B; Conil JM; Cougot P; Decun JF; Archambaud M; Seguin T; Chabanon G; Virenque C; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):360-9. PubMed ID: 16119511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.
    Jaruratanasirikul S; Sriwiriyajan S; Ingviya N
    J Pharm Pharmacol; 2002 Dec; 54(12):1693-6. PubMed ID: 12542901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations.
    LeBel M; Spino M
    Clin Pharmacokinet; 1988 Feb; 14(2):71-95. PubMed ID: 3282748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
    Ulldemolins M; Roberts JA; Rello J; Paterson DL; Lipman J
    Clin Pharmacokinet; 2011 Feb; 50(2):99-110. PubMed ID: 21142293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of beta-lactam antibiotics.
    MacGowan AP; Bowker KE
    Clin Pharmacokinet; 1998 Nov; 35(5):391-402. PubMed ID: 9839090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS; Summers KK; Hardin TC
    Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Echeverría O; Gómez-Lus ML; Prieto J
    J Antimicrob Chemother; 2005 Feb; 55(2):209-13. PubMed ID: 15650000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen.
    Periti P; Mazzei T
    J Chemother; 1999 Feb; 11(1):11-27. PubMed ID: 10078776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations.
    Mouton JW; Vinks AA
    J Antimicrob Chemother; 1996 Jul; 38(1):5-15. PubMed ID: 8858451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters.
    Adembri C; Ristori R; Chelazzi C; Arrigucci S; Cassetta MI; De Gaudio AR; Novelli A
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):471-5. PubMed ID: 20570290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marbofloxacin disposition after intravenous administration of a single dose in wild mallard ducks (Anas platyrhynchos).
    Garcia-Montijano M; de Lucas JJ; Rodríguez C; González F; San Andrés MI; Waxman S
    J Avian Med Surg; 2012 Mar; 26(1):6-10. PubMed ID: 22645833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.
    Conte JE; Golden JA; Kelly MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Jun; 25(6):523-9. PubMed ID: 15885987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.
    Nau R; Sörgel F; Prange HW
    Clin Pharmacokinet; 1998 Sep; 35(3):223-46. PubMed ID: 9784935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
    Cousson J; Floch T; Vernet-Garnier V; Appriou M; Petit JS; Jovenin N; Lamiable D; Hoizey G
    Pathol Biol (Paris); 2005; 53(8-9):546-50. PubMed ID: 16023303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.